glp-1 heart issues Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide | Cardiovascular Diabetology What Are GLP-1 Agonists and

We talk about what the medication does and doesn't do : it reduces appetite signals, but it doesn't substitute for protein intake, sleep, or activity

Abstract Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have redefined the management of obesity and type 2 diabetes mellitus, producing sustained and clinically meaningful reductions in total body weight alongside significant cardiometabolic benefits

According to the Centers for Disease Control and Prevention (CDC), long-term success often requires a combination of nutrition, physical activity, behavioral changes, and the appropriate medical interventions

doi: 10.1016/j.lfs.2020.118548 [DOI] [PMC free article] [PubMed] [Google Scholar] 177.Saengboonmee C, Sorin S, Sangkhamanon S, et al